Clinical trials: PEG-rhG-CSF

Diabetes Mellitus, Type 1

ATG-GCSF in New Onset Type 1 Diabetes

• Completed
• Age: 12 to 45 years
• Phase 2
• Results posted

This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects…

Trial name

ATG-GCSF (NCT02215200)

Testing

Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF)

Where

13 sites in United States

Volunteers

89 people

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)